Michael Reinehr

Michael Reinehr

Auto-generated profile, based on publicly available information

Michael Reinehr

University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in Science Robotics
Verified
Journal Article
Closed access
RDR. Dreyfus
R. Dreyfus
QBQ. Boehler
Q. Boehler
SLS. Lyttle
S. Lyttle
PGP. Gruber
P. Gruber
JLJ. Lussi
J. Lussi
BNBradley Nelson
Bradley Nelson
Treating vascular diseases in the brain requires access to the affected region inside the body. This is usually accomplished through a minimally invasive technique that involves the use of long, thin devices, such as wires and tubes, that are manually maneuvered by a clinician within the bloodstream. By pushing, pulling, and twisting, these devices are navigated through the tortuous pathways of the blood vessels. The outcome of the procedure heavily relies on the clinician’s skill and the device’s ability to navigate to the affected target region in the bloodstream, which is often inhibited by tortuous blood vessels. Sharp turns require high flexibility, but this flexibility inhibits translation of proximal insertion to distal tip advancement. We present a highly dexterous, magnetically steered continuum robot that overcomes pushability limitations through rotation. A helical protrusion on the device’s surface engages with the vessel wall and translates rotation to forward motion at every point of contact. An articulating magnetic tip allows for active steerability, enabling navigation from the aortic arch to millimeter-sized arteries of the brain. The effectiveness of the magnetic continuum robot has been demonstrated through successful navigation in models of the human vasculature and in blood vessels of a live pig.

10 June 2021 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
SKSimon Kraler
Simon Kraler
PLPeter Libby
Peter Libby
PEPaul C. Evans
Paul C. Evans
AAAlexander Akhmedov
Alexander Akhmedov
MSMartin O. Schmiady
Martin O. Schmiady
TLThomas F. Lüscher
Thomas F. Lüscher
Fueled by the global surge in aging, atherosclerotic cardiovascular disease reached pandemic dimensions putting affected individuals at enhanced risk of myocardial infarction, stroke, and premature death. Atherosclerosis is a systemic disease driven by a wide spectrum of factors, including cholesterol, pressure, and disturbed flow. Although all arterial beds encounter a similar atherogenic milieu, the development of atheromatous lesions occurs discontinuously across the vascular system. Indeed, the internal mammary artery possesses unique biological properties that confer protection to intimal growth and atherosclerotic plaque formation, thus making it a conduit of choice for coronary artery bypass grafting. Its endothelium abundantly expresses nitric oxide synthase and shows accentuated nitric oxide release, while its vascular smooth muscle cells exhibit reduced tissue factor expression, high tPA (tissue-type plasminogen activator) production and blunted migration and proliferation, which may collectively mitigate intimal thickening and ultimately the evolution of atheromatous plaques. We aim here to provide insights into the anatomy, physiology, cellular, and molecular aspects of the internal mammary artery thereby elucidating its remarkable resistance to atherogenesis. We propose a change in perspective from risk to resilience to decipher mechanisms of atheroresistance and eventually identification of novel therapeutic targets presently not addressed by currently available remedies.

1 September 2020 in Immunobiology
Verified
Journal Article
Open access
Daniela Mihic-ProbstDaniela Mihic-Probst
Daniela Mihic-Probst
MRMichael Reinehr
Michael Reinehr
SDSusanne Dettwiler
Susanne Dettwiler
IKIsabel Kolm
Isabel Kolm
CBChristian Britschgi
Christian Britschgi
ERElisabeth J Rushing
Elisabeth J Rushing
Immune checkpoint inhibitory (ICI) therapy represents a novel approach in a variety of cancers, with impressive survival benefit. With ICIs, however, a new spectrum of immune related adverse events (irAE) including life threatening hypohysitis has emerged. This autopsy study aimed to investigate inflammatory cells, PD-1 and PD-L1 expression in cases of patients who developed hypophysitis and involvement of other organs. We analysed 6 patients, who were treated with ICIs and developed hypophysitis. Two received an additional MAP-kinase inhibitor, MEK-inhibitor and cytotoxic chemotherapy. Besides the pituitary gland, all investigated adrenal glands (5/5) were affected; three cases had other organs involved (liver (2/6), thyroid (2/6), lung (1/6), myocardium (1/6), colon (1/6). The inflammatory cells of involved organs were further specified and PD1 and PDL-1 expression was analyzed using immunohistochemistry. We observed that patients treated with ICIs alone showed T-cell predominant lymphocytic infiltrates, whereas patients receiving additional therapies demonstrated an increase in B- and T-lymphocytes. Surprisingly, the dominant inflammatory population was not T-cell, but type 2 macrophages. CD25 positive T-regs were sparse or absent. Our study suggests that T cell activation is only partially responsible for irAE. ICI therapy interaction with CTLA-4, PD-1 and PDL-1 in type 2 macrophages appears to result in disturbance of their control. Furthermore, depletion of T-regs seems to contribute significantly. Our findings with simultaneous pituitary and adrenal gland involvement underlines the systemic involvement as well as the importance of monitoring cortisol levels to avoid potentially life threatening hypocortisolism.

28 December 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
JGJohannes Grimm
Johannes Grimm
JNJuliane Nell
Juliane Nell
AHAndreas Hillenbrand
Andreas Hillenbrand
DHDoris Henne-Bruns
Doris Henne-Bruns
JSJulian Schmidberger
Julian Schmidberger
TBThomas FE Barth
Thomas FE Barth
Background: Alveolar (AE) and cystic echinococcosis (CE) in humans are caused by the metacestode of the tapewormsEchinococcus multilocularisandEchinococcus granulosus sensu lato (s.l.). Immunohistochemistry with the monoclonal antibodies (mAb) Em2G11, specific for AE, and the mAb EmG3, specific for AE and CE, is an important pillar of the histological diagnosis of these two infections. Our aim was to further evaluate mAb EmG3 in a diagnostic setting and to analyze in detail the localization, distribution, and impact ofsmallparticles ofEchinococcusmultilocularis(spems) andsmallparticles ofEchinococcusgranulosuss.l. (spegs) on lymph nodes.Methodology/principal findings: We evaluated the mAb EmG3 in a cohort of formalin-fixed, paraffin embedded (FFPE) specimens of AE (n = 360) and CE (n = 178). These samples originated from 156 AE-patients and 77 CE-patients. mAb EmG3 showed a specific staining of the metacestode stadium ofE.multilocularisandE.granulosus s.l. and had a higher sensitivity for spems than mAb Em2G11. Furthermore, we detected spegs in the surrounding host tissue and in almost all tested lymph nodes (39/41) of infected patients. 38/47 lymph nodes of AE showed a positive reaction for spems with mAb EmG3, whereas 29/47 tested positive when stained with mAb Em2G11. Spegs were detected in the germinal centers, co-located with CD23-positive follicular dendritic cells, and were present in the sinuses. Likewise, lymph nodes with spems and spegs in AE and CE were significantly enlarged in size in comparison to the control group.Conclusions/significance: mAb EmG3 is specific for AE and CE and is a valuable tool in the histological diagnosis of echinococcosis. Based on the observed staining patterns, we hypothesize that the interaction between parasite and host is not restricted to the main lesion since spegs are detected in lymph nodes. Moreover, in AE the number of spems-affected lymph nodes is higher than previously assumed. The enlargement of lymph nodes with spems and spegs points to an immunological interaction with the small immunogenic particles (spems and spegs) ofEchinococcus spp.

7 October 2021 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
LBLudovica Blumetti
Ludovica Blumetti
MPMaria Luisa De Perna
Maria Luisa De Perna
MRMichael Reinehr
Michael Reinehr
GPGiovanni Pedrazzini
Giovanni Pedrazzini
Background: Eosinophilic myocarditis (EM) is a rare and potentially life-threatening form of myocarditis, frequently (but not always) associated with eosinophilia, and presents with acute chest pain, or signs and symptoms of acute or chronic heart failure. Eosinophilic myocarditis has various aetiologies, including eosinophilic granulomatosis with polyangiitis (EGPA). Case summary: A 52-year-old female with a long-standing history of asthma, acral paraesthesia, subcutaneous nodules, and recurrent chest pain treated with anti-inflammatory drugs was admitted to our hospital with chest pain, repolarization disturbances, eosinophilia, and increased troponin levels. After an initial evaluation by coronary angiography, echocardiography and cardiac magnetic resonance, a definitive diagnosis of EM was made with the help of an endomyocardial biopsy. The aetiological diagnosis of EM as a manifestation of tissue involvement in EGPA was concluded after ruling out other possible causes of eosinophilia and with the help of other diagnostic criteria for EGPA (asthma, eosinophilia, and neuropathy). Therefore, we started with a high dosage of glucocorticoids, and attained relief of symptoms and normalization of eosinophilic count after a few days. Discussion: In cases of myocarditis (particularly if associated with eosinophilia), EM is a manifestation of EGPA and should be considered for a prompt differential diagnosis. Endomyocardial biopsy represents the gold standard for the diagnosis of EM. The mainstay of therapy for EM is immunosuppressive drugs to help prevent its evolution to a fulminant form and chronic progression towards restrictive cardiomyopathy.

1 August 2022 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
JGJulia Geiger
Julia Geiger
SKSabine Kroiss
Sabine Kroiss
MRMichael Reinehr
Michael Reinehr
DEDésirée Ehrlinspiel
Désirée Ehrlinspiel
Martin SchweigerMartin Schweiger
Martin Schweiger
WKWalter Knirsch
Walter Knirsch
A 10-year-old active ballet dancer presented for diagnostic work up of an innocent cardiac murmur without any cardiac symptoms. On echocardiography, a large left ventricular (LV) indeterminate mass was identified (Panel A, see Supplementary material online , Supplementary Material S1). A comprehensive cardiac magnetic resonance imaging (MRI) depicted a large mass (diameter 8 cm) within the LV cave passing through the myocardium to the pericardial space of the LV free wall without signs of pericardial infiltration and effusion (Panel B). A short-axis stack of CINE steady-state free precession (SSFP) sequences demonstrated that the intraventricular mass component almost completely occupied the LV during systole in midventricular and apical parts (Panels C and D, see Supplementary material online , Supplementary Material S2). The LV inlet and outlet were not obstructed as seen on CINE SSFP (Panel E). There was no mitral valve insufficiency or chordal retraction; however, the papillary muscles were included within the mass. Left ventricular function was preserved with an ejection fraction above 70% excluding the mass. T1-weighted, triple inversion recovery sequences revealed a predominantly fat isointense mass with several septations (Panels F and G).